← FDA DRUG APPROVALS

FDA ANDA · ANDA077660

ESCITALOPRAM OXALATE

Sponsor: RISING

APPLICATION
ANDA077660
TYPE
ANDA
ORIGINAL APPROVAL
2007-07-31
LATEST ACTION
2014-07-17
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

ESCITALOPRAM OXALATEDiscontinued
ESCITALOPRAM OXALATE EQ 20MG BASE · CAPSULE · ORAL
ESCITALOPRAM OXALATEDiscontinued
ESCITALOPRAM OXALATE EQ 5MG BASE · CAPSULE · ORAL
ESCITALOPRAM OXALATEDiscontinued
ESCITALOPRAM OXALATE EQ 10MG BASE · CAPSULE · ORAL

Approval history

2014-07-17Labeling · Supplement 4 · standardAP
2009-04-06Labeling · Supplement 1AP
2009-02-13Labeling · Supplement 2AP
2007-07-31Original — Other Important Information from FDA ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →